Certara, Inc. (NASDAQ:CERT) Position Cut by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund trimmed its holdings in Certara, Inc. (NASDAQ:CERT) by 7.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 57,453 shares of the company’s stock after selling 4,805 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Certara were worth $612,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CERT. Harbor Capital Advisors Inc. grew its holdings in Certara by 18.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 20,144 shares of the company’s stock worth $236,000 after buying an additional 3,136 shares in the last quarter. Atria Investments Inc grew its holdings in Certara by 21.6% in the 3rd quarter. Atria Investments Inc now owns 19,743 shares of the company’s stock worth $231,000 after buying an additional 3,501 shares in the last quarter. TimesSquare Capital Management LLC grew its holdings in Certara by 3.1% in the 3rd quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company’s stock worth $11,202,000 after buying an additional 29,090 shares in the last quarter. Versor Investments LP bought a new position in Certara in the 3rd quarter worth approximately $162,000. Finally, Geneva Capital Management LLC grew its holdings in Certara by 0.7% in the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after buying an additional 37,392 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CERT. Stephens restated an “overweight” rating and issued a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. William Blair restated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Robert W. Baird cut their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. TD Cowen began coverage on Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 target price for the company. Finally, Barclays upped their target price on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.83.

Certara Price Performance

Shares of NASDAQ:CERT opened at $11.94 on Tuesday. Certara, Inc. has a one year low of $9.41 and a one year high of $19.87. The stock has a fifty day moving average of $12.48 and a 200-day moving average of $11.63. The company has a market capitalization of $1.92 billion, a PE ratio of -59.70, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.